Our read is that taking nicotinamide is partially supported, with potential benefits for skin health and certain conditions, but also notable concerns regarding sirtuin inhibition and methylation pathways.
Our read is that nicotinamide shows promise for skin health, potentially reducing inflammation, assisting with conditions like rosacea and acne, and preventing certain types of skin cancer, as suggested by Andrew Huberman and Rhonda Patrick. It may also offer benefits for muscle NAD+ levels and in specific therapeutic contexts like ALS and glaucoma, according to Peter Attia and Andrew Huberman.
However, Peter Attia and Paul Saladino caution against high doses due to its inhibitory effect on sirtuins and its potential to drive methylation pathways, leading to elevated homocysteine levels and anxiety. David Sinclair's lab and R. de Cabo's lab also found that nicotinamide does not extend lifespan in studies.
Andrew Huberman suggests oral niacinamide supplementation can be taken at 1000mg per day, divided into 2x 500mg doses. For skincare, Bryan Johnson includes niacinamide in a daily protocol with face washing, mineral sunscreen, moisturizing, vitamin C, hyaluronic acid, and tretinoin.
Peter Attia and Paul Saladino strongly advise avoiding high doses of nicotinamide unless the patient has cancer, as it inhibits sirtuins. Paul Saladino further notes that nicotinamide may inhibit sirtuin activity and that high doses can deplete methyl groups, potentially leading to anxiety. David Sinclair's lab and R. de Cabo's lab found that nicotinamide does not extend lifespan in studies.
The verdict would change if new evidence emerged demonstrating that nicotinamide does not inhibit sirtuins at commonly used doses, or if studies showed a clear lifespan extension benefit. Conversely, stronger evidence of significant adverse effects on methylation pathways or other critical biological processes would further diminish support.
The intervention improves the primary outcome at standard doses in healthy adults.
Mechanistic and trial evidence converge on a real, replicable effect.
Nicotinamide acts as a feedback inhibitor of sirtuins, slowing NAD+ production.
Nicotinamide may prevent certain types of skin cancer, as suggested by a study from Australia.
Oral nicotinamide can inhibit repair enzymes (sirtuins, PARPs) in the liver before conversion to NAD+.
Confounding and publication bias inflate the apparent benefit.
Most of the support comes from short or small studies.
Most of the support comes from short or small studies.
The headline effect shrinks once you account for trial quality.
High doses of nicotinamide should be avoided unless the patient has cancer, as it inhibits sirtuins.